Compare EEFT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | PHVS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1996 | 2020 |
| Metric | EEFT | PHVS |
|---|---|---|
| Price | $72.99 | $33.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $95.00 | $41.82 |
| AVG Volume (30 Days) | ★ 671.5K | 464.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.05 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $4,244,200,000.00 | N/A |
| Revenue This Year | $8.17 | N/A |
| Revenue Next Year | $5.97 | N/A |
| P/E Ratio | $88.52 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $62.50 | $19.56 |
| 52 Week High | $98.52 | $36.60 |
| Indicator | EEFT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | N/A |
| Support Level | $72.35 | N/A |
| Resistance Level | $75.49 | N/A |
| Average True Range (ATR) | 2.67 | 0.00 |
| MACD | -1.16 | 0.00 |
| Stochastic Oscillator | 14.85 | 0.00 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing, and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.